A CK2-targeted Pt(IV) prodrug to disrupt DNA damage response
Author:
Funder
National Natural Science Foundation of China
National Science and Technology Major Foundation of China
Jiangsu Province Natural Science Foundation
Fundamental Research Funds
Publisher
Elsevier BV
Subject
Cancer Research,Oncology
Reference47 articles.
1. Platinum compounds: a new class of potent antitumour agents;Rosenberg;Nature,1969
2. The resurgence of platinum-based cancer chemotherapy;Kelland;Nat. Rev. Cancer,2007
3. The role of DNA repair pathways in cisplatin resistant lung cancer;O'Grady;Cancer Treat. Rev.,2014
4. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer;Cobo;J. Clin. Oncol.,2007
5. DNA damage response-a double-edged sword in cancer prevention and cancer therapy;Tian;Cancer. Lett.,2015
Cited by 43 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Glycyrrhetinic Acid as a Hepatocyte Targeting Ligand-Functionalized Platinum(IV) Complexes for Hepatocellular Carcinoma Therapy and Overcoming Multidrug Resistance;Journal of Medicinal Chemistry;2024-05-10
2. Synergetic impact of combined navoximod with cisplatin mitigates chemo-immune resistance via blockading IDO1+ CAFs-secreted Kyn/AhR/IL-6 and pol ζ-prevented CIN in human oral squamous cell carcinoma;Life Sciences;2023-12
3. The regulatory subunits of CK2 complex mediate DNA damage response and virulence in Candida Glabrata;BMC Microbiology;2023-10-28
4. Circumventing drug resistance through a CK2-targeted combination via attenuating endogenous AhR-TLS-promoted genomic instability in human colorectal cancer cells;Food and Chemical Toxicology;2023-06
5. Dual–target platinum(IV) complexes reverse cisplatin resistance in triple negative breast via inhibiting poly(ADP–ribose) polymerase (PARP–1) and enhancing DNA damage;Bioorganic Chemistry;2023-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3